Genmab — December 2017
-
uha - pas på med at begå hybris Raun - en fond, der bare lige kaster over en halv mia kroner i en shortposition er ikke sådan at spøge med...
-
Som jeg læser shorten så måtte deres superprogram på arbejde i går og hælde aktier ud, flere end de bryder sig om. I skal ikke undervurdere betydningen heraf. Der er helt sikker nogen der holder øje med denne case og som har midlerne til at iværksætte en shortsquezze og tjene kassen på bekostning af deres program.
-
tweet on AL amyloidosis https://twitter.com/BursatilBiotech/status/943903615126851586
-
Highlights from ASH 2017: Research Update on AL amyloidosis http://www.arci.org/blog-1/2017/12/14/highlights-from-ash-2017-research-update
-
video - Major breakthroughs in AL amyloidosis treatment from ASH 2017 - https://www.vjhemonc.com/video/fpeohrztdaq-major-breakthroughs-in-al-amyloidosis-treatment-from-ash-2017/
-
Et lille sidespring. Hermed min analyse fra i dag på Nuevolution lægemiddeludviklingsmaskine. http://www.proinvestor.com/aktieanalyser/255/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
